Biogen's LEQEMBI Shows Real-World Stability in 75% of Early Alzheimer’s Patients — Biogen Inc.

Event summary

Biogen and Eisai's LEQEMBI therapy showed 75.9% of early Alzheimer’s patients remained stable over an average of 17 months, with 6.6% improving.
The real-world LEADER study included 432 patients across diverse U.S. clinical settings, with consistent results across sex, race, ethnicity, and APOE genotype.
87% of patients chose to remain on LEQEMBI treatment, indicating high patient retention.
ARIA (amyloid-related imaging abnormalities) was observed in 12.3% of patients, with most cases being asymptomatic and mild.

The big picture

Biogen and Eisai's real-world data for LEQEMBI reinforces its role as a leading therapy for early Alzheimer’s, targeting both soluble and insoluble amyloid-beta. The consistent results across diverse patient groups highlight its potential to slow cognitive decline, positioning it as a key player in the competitive landscape of neurodegenerative disease treatments.

What we're watching

Regulatory Expansion: Whether LEQEMBI's approval in additional countries will accelerate its global commercialization.
Long-Term Efficacy: The pace at which continued treatment with LEQEMBI can sustain stability or improvement in early Alzheimer’s patients.
Competitive Dynamics: How Biogen and Eisai will position LEQEMBI against emerging Alzheimer’s therapies in the market.